Abstract 915P
Background
To compare survival outcomes and toxic effects among patients with newly diagnosed nonmetastatic nasopharyngeal carcinoma (NPC) when treated with Intensity modulated radiotherapy (IMRT) versus IMRT + carbon-ion radiotherapy (CIRT).
Methods
We performed a retrospective propensity score matching analysis (1:1) of patients treated with IMRT and IMRT + CIRT. Survival was estimated using the Kaplan–Meier method. Multivariate Cox proportional hazards regression analysis was used to identify the independent predictors of survival. We examined the association between risk factors and adverse events (AEs) using Chi-squared tests. AEs analyses were performed using a Cox model and logistic regression.
Results
109 patients who received IMRT + CIRT were included and the median follow-up time was 20.6 months (range: 4.6-82 months). There were no statistically significant differences in locoregional failure–free survival, distant metastasis–free survival, disease-free survival, or overall survival between the two groups, but potentially better in IMRT + CIRT group (P > 0.05, respectively). Nodal boost was the only significant factor associated with LRFS and DFS on multivariable analysis. 37 patients (34.0%) developed grade 3 acute OMs and no grade 4 acute OMs were observed in IMRT + CIRT group. All patients in IMRT + CIRT group developed grade 1 dermatitis. IMRT +CIRT treatment was associated with a significant trend of lower grades of OM and dermatitis (P < 0.05, respectively). Any severe (ie, grade 3) chronic AEs, such as xerostomia, skin fibrosis, temporal lobe necrosis, osteoradionecrosis, or radiation-induced optic neuropathy, was not observed.
Conclusions
IMRT + CIRT for primary nonmetastatic NPC was associated with significantly reduced oral mucositis and dermatitis compared with full course of IMRT, with excellent survival outcomes. Patients with persistent disease after primary treatment and treated with nodal boost had a worse outcome. More accurate assessments of IMRT + CIRT to primary nonmetastatic NPC patients will be imperative.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The study was funded by the Clinical research on health industry of Shanghai Health Commission (grant numbers: 20214Y0025) The study was funded by the Clinical research of Shanghai Pudong District Health Commission (grant numbers: PW2022A-41).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
932P - Survival in patients with relapsed/metastatic head and neck squamous cell carcinoma (HNSCC) treated with pembrolizumab or cetuximab-based therapy: A real-worlddata study with the TriNetX platform
Presenter: Lisardo Ugidos De La Varga
Session: Poster session 12
934P - Antitumor activity and safety profile of camrelizumab plus docetaxel, cisplatin, and capecitabine for induction therapy in advanced stage hypopharyngeal carcinoma
Presenter: Hongli Gong
Session: Poster session 12
938P - Nivolumab (nivo) in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN): real-world effectiveness, quality of life (QoL) of patients and their caregivers in France (ProNiHN study)
Presenter: Christophe Le Tourneau
Session: Poster session 12
939P - Efficacy and safety of a novel anti-EGFR ADC MRG003 in recurrent or metastatic squamous cell carcinoma of the head and neck patients
Presenter: Liqiong Xue
Session: Poster session 12
940P - Salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck included in the phase II TOPNIVO trial
Presenter: Khalil Saleh
Session: Poster session 12
941P - Risk factors for progressive disease after immune checkpoint inhibitors (ICIs) in advanced head and neck squamous cell carcinoma (HNSCC): Who might not be candidate for ICI?
Presenter: Seo Yoon Jang
Session: Poster session 12